NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...
Vanda Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
Vanda (VNDA) Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals Q3 Earnings Call Highlights
Vanda: Q3 Earnings Snapshot
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Vanda Pharma Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals FY2026 Revenue expected to be more than $240.000M vs $248.797M Est
Vanda Pharma Q3 EPS $(0.37) Beats $(0.68) Estimate, Sales $69.815M Beat $69.202M Estimate
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Vanda Pharmaceuticals Announces Phase III Study Results Showing Significant Reduction In GLP-1 Therapy-Associated Vomiting With NEREUS
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches
Vanda puts anxiety drug’s development on ice after Phase III fail
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals stock falls after anxiety drug trial fails
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.